ACHILLES is a Doctoral Network (DN) program designed to train the next generation of leaders in hemato-oncology, with a focus on the development of novel therapeutic solutions for hematological malignancies. The network brings together 14 institutions from 10 EU countries and one associated state, along with partners from the biotechnology and drug discovery sectors, including two European policy leaders in hematology, the European Hematology Association (EHA) and the European School of Hematology (ESH). Through this collaboration, ACHILLES will train 16 Doctoral Candidates (DCs) to develop essential skills in experimental hemato-oncology, including the design, development, and preclinical validation of innovative therapies. ACHILLES is structured around three key scientific objectives (SOs): (1) creating novel experimental models and analytical methods, (2) exploring the oncogenic mechanisms of hematologic malignancies, and (3) developing and validating new therapies, especially targeted treatments for leukemia and lymphoma. The program will integrate cutting-edge technologies such as AI, multi-omics, and computational modeling to push the boundaries of current research and therapy development. These innovations will be applied to generate better diagnostic tools, predict treatment responses, and optimize therapeutic strategies. With a patient-centered approach, ACHILLES aims to foster both academic and industrial collaboration, bridging gaps between scientific research and clinical application. This initiative aligns with the EU's Beating Cancer Plan, with a particular focus on improving survival rates and treatment accessibility, especially in Widening Countries. Through strong academic-industrial partnerships, ACHILLES will help create a sustainable impact on the field of hemato-oncology, advancing research, therapies, and ultimately the health outcomes of leukemia and lymphoma patients worldwide.